Genprex

News

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read More

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Read More

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex’s Acclaim-2 and Acclaim-3 clinical trials

Read More


Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators 

Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Read More

Genprex to Present at Upcoming BIO CEO & Investor Conference

Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes

Read More


Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.

Read More

Genprex Provides Business Update and Outlook for 2024 

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024

Poised for FDA guidance regarding diabetes gene therapy program in 2024

Read More

Genprex to Present at BIO-Europe 2023 Conference 

Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC

Read More